OSE Pharma SA (OSE) News
Follow OSE Pharma SA (OSE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
OSE Immunotherapeutics Reports Positive Phase 2 Combi-TED Results
OSE Immunotherapeutics said the primary endpoint was met. One-year overall survival was 47% with Tedopi plus docetaxel and 46% with Tedopi plus nivolumab, versus 29% with docetaxel alone; no unexpected safety signals wer
EQUITY | Oct 19, 2026, 05:32 AM UTC
L
OSE Immunotherapeutics SA (OSE) Cash €11.1M; ARTEMIA Interim Readout Slips to Early-2027
OSE Immunotherapeutics SA reported €11.1M cash as of June 30, 2026 (vs €17.0M at Mar 31) and said its bridge financing plus cash funds operations through Dec 2026. The ARTEMIA Phase 3 futility analysis is now expected ea
NEWS | Sep 28, 2026, 05:32 AM UTC
L
OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update
Nantes, France, September 28, 2026 — 7:30am CET — OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immun
NEWS | Sep 28, 2026, 05:32 AM UTC
L
OSE Immunotherapeutics SA (OSE) To Present Combi-TED Phase 2 Topline Results at ESMO 2026
OSE Immunotherapeutics SA said topline results from the Phase 2 Combi-TED trial of Tedopi in metastatic NSCLC were selected for oral presentation at ESMO 2026. The study tested Tedopi plus nivolumab or docetaxel vs docet
NEWS | Sep 23, 2026, 05:32 AM UTC
L
OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting
Nantes, France, September 23, 2026 — 7:30am CET — OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immun
NEWS | Sep 23, 2026, 05:32 AM UTC
L
OSE Immunotherapeutics gets first patient dosed in RENGEVITY-201
OSE Immunotherapeutics said its licensee Veloxis Pharmaceuticals announced the first patient has been dosed in RENGEVITY-201, a Phase 2 trial evaluating pegrizeprument (VEL-101) for kidney transplant rejection preventio
EQUITY | Sep 09, 2026, 04:03 PM UTC
M
Lusvertikimab posts strong phase II ulcerative colitis results, advancing
Lusvertikimab, an anti-IL-7 receptor antibody, reported robust efficacy and safety in phase II ulcerative colitis trials, with consistent improvements across clinical, endoscopic and histological endpoints. Development i
EQUITY | Sep 02, 2026, 05:32 PM UTC
L
OSE Immunotherapeutics schedules KOL webcast on lusvertikimab Sept 2, 2026
OSE Immunotherapeutics will host a KOL webcast dedicated to lusvertikimab on September 2, 2026.
EQUITY | Aug 28, 2026, 05:37 AM UTC